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OBJECTIVE— We determined the longitudinal association of glucose metabolism with ret-
inopathy in a sample of the Australian population.
RESEARCH DESIGN AND METHODS— The Australian Diabetes Obesity and Life-
style (AusDiab) study is a national, longitudinal study of adults aged 25 years from 42 ran-
domly selected areas of Australia. Retinopathy was assessed at baseline in 1999–2000 and 5
years later in 2004–2005 in participants identified as having diabetes (based on self-report and
oral glucose tolerance test) and impaired glucose metabolism and in a random sample with
normal glucose tolerance. Complete retinal data were available for 1,192 participants. Photo-
graphs were graded at two time points according to a simplified version of the Wisconsin grading
system.
RESULTS— The 5-year incidences of retinopathy were 13.9 and 3.0% among those with
known and newly diagnosed diabetes at baseline, respectively. Of those who developed incident
newly diagnosed diabetes at follow-up, 11.9% had retinopathy at baseline compared with 5.6%
of those who did not progress to incident newly diagnosed diabetes (P  0.037). After adjust-
ment for factors identified as risk factors for diabetes, individuals with retinopathy signs at
baseline were twice as likely to develop incident newly diagnosed diabetes compared with those
who did not have retinopathy signs at baseline.
CONCLUSIONS— The 5-year incidence of retinopathy was 13.9% among individuals with
known diabetes. Nondiabetic individuals with retinopathy signs at baseline had a twofold higher
risk of developing incident newly diagnosed diabetes 5 years later. This result provides further
evidence that mild retinopathy signs may be a preclinical marker of underlying microvascular
disease and future diabetes risk.
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D iabetic retinopathy is a commoncomplication of diabetes and re-mains a leading cause of visual loss
throughout the world, despite the avail-
ability of effective health care interven-
tions. Although the epidemiology of
retinopathy has been extensively studied,
there are few national population-based
studies on the incidence and risk factors
for diabetic retinopathy, and only a lim-
ited number have assessed the develop-
ment of retinopathy across the spectrum
of glucose values from normal glucose tol-
erance to the diabetic range (1,2).
Contemporary data on the incidence
of retinopathy in individuals with differ-
ent levels of abnormal glucose metabo-
lism is important in determining the
relative contribution of glycemia to the
development of retinopathy. There is now
increasing evidence that retinopathy signs
typical of diabetes are in fact present in up
to 10% of those with normal glucose tol-
erance (3). In individuals with and with-
out diabetes, these signs have been
associated with an increased risk of stroke
(4), congestive heart failure (5), cardio-
vascular disease, and mortality (6) and the
subsequent development of diabetes (7),
independent of other well-established
risk factors. We now report on the 5-year
incidence and risk factors for retinopathy
across categories of glucose metabolism
and the association of retinopathy signs
detected at baseline with subsequent de-
velopment of diabetes.
RESEARCH DESIGN AND
METHODS— The population, meth-
ods, and response rates of Australian Di-
abetes Obesity and Lifestyle (AusDiab)
study are discussed in detail elsewhere
(8). In brief, the AusDiab study was a pop-
ulation-based study of 11,247 people
aged 25 years, from 42 randomly se-
lected urban and rural areas of Australia,
conducted in 1999–2000. The response
rate for the baseline survey was 55.3%
(n 11,247), and the follow-up response
rate in 2004–2005 was 60.6% (6,537/
10788); 459 individuals were ineligible
for the follow-up study because of a ter-
minal illness or death or because they re-
fused further contact.
The study was approved by the ethics
committee of the International Diabetes
Institute. Informed consent for the study
was obtained from all participants.
At baseline, people identified through
the AusDiab study as having diabetes
(known and newly diagnosed by oral glu-
cose tolerance test in the survey), im-
paired glucose metabolism (defined by
impaired fasting glucose or impaired glu-
cose tolerance), and a random sample of
people with normal glucose tolerance
(NGT) were invited to participate in the
baseline complications survey. Of 2,773
participants invited for the complications
component, 2,476 attended at baseline
(overall response rate 89%, 91% in those
with diabetes and 88% in those without
diabetes). Of the 2,476 participants in
this substudy, we excluded 1,126
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(45.5%) who did not attend the 5-year
follow-up examination and 158 (6.4%)
who had ungradable photographs at ei-
ther baseline or follow-up, leaving 1,192
participants for this analysis (see Fig. 1 of
an online appendix, available at http://
dx.doi.org/10.2337/dc07-1707). Com-
pared with nonresponders, responders
included in the analysis were younger
(mean age 56 vs. 61 years, P  0.001),
were less likely to smoke (10 vs. 15%, P
0.001), had a slightly lower prevalence of
retinopathy (8 vs. 11%, P  0.016), and
had lower A1C (5.7 vs. 5.8%, P 0.004)
at baseline. There were no baseline differ-
ences in the percentage of men (49 vs.
51%, P 0.505), the percentage of those
with hypertension (52 vs. 56%, P 
0.123), mean total cholesterol (5.7 vs.
5.6mmol/l, P 0.241), or duration of di-
abetes among those with known diag-
nosed diabetes (8.5 vs. 8.2 years, P 
0.593).
Diabetes classification was based on
plasma glucose results, using the 1999
World Health Organization diabetes clas-
sification (9). Incident newly diagnosed
diabetes at 5 years was defined as an indi-
vidual without known diagnosed diabetes
or newly diagnosed diabetes at baseline in
whom diabetes was diagnosed at the fol-
low-up examination. Incident known di-
agnosed diabetes at 5 years was defined as
an individual without known diagnosed
diabetes or newly diagnosed diabetes at
baseline in whom diabetes was diagnosed
between baseline and follow-up by the in-
dividual’s physician.
Assessment of retinopathy
Retinal photographs were taken at base-
line and at follow-up with a nonmydriatic
retinal camera (Canon CR6-45NM). At
the baseline examination, the camera had
an adapter fitted with a Sony three-chip
charge-coupled device. However, this
camera was updated to a digital camera
backing for the follow-up visit in 2004–
2005, resulting in higher resolution and
quality of digital images. Two photo-
graphic fields, one centered on the optic
disc and the second on the macula, were
taken of each eye after dark adaptation
without the use of dilating drops. One as-
sessor, masked to all participant informa-
tion, graded the photographs at baseline
and follow-up. Level of retinopathy was
defined according to a simplified version
of the Wisconsin grading system (10),
with the classification of an individual be-
ing based on the grading of the worst eye.
A random sample of 167 retinal photo-
graphs at baseline (with and without ret-
inopathy) were regraded (by the same
assessor) to assess the internal validity of
the grading. Overall there was a high de-
gree of agreement between the first and
second grading of retinopathy ( 
0.732, unweighted).
To identify participants with incident
retinopathy, we selected images from all
participants with any retinopathy at fol-
low-up (as determined from retinal im-
ages) and then verified the absence of any
retinopathy lesions in the baseline im-
ages. Incident retinopathy was defined as
the presence of retinal microaneurysm
and/or hemorrhage at the 5-year follow-
up. All cases of incident retinopathy were
adjudicated by a retinal specialist.
Other measurements
In 1999 –2000, fasting plasma glucose
(FPG) and 2-h plasma glucose levels were
determined by a glucose oxidase method
using an Olympus AU600 automated an-
alyzer (Olympus Optical, Tokyo, Japan),
and in 2004–2005, a spectrophotomet-
ric-hexokinase method with a Roche
Modular system (Roche Diagnostics, In-
dianapolis, IN) was used. Details on the
assays used in the studies can be found in
detail elsewhere (8). Urinary albumin and
creatinine were also determined in a spot
morning urine specimen by enzymatic
methods (Olympus AU600 analyzer). Se-
rum triglycerides, total cholesterol, and
HDL cholesterol were measured by simi-
lar enzymatic methods at baseline. For to-
tal A1C analysis, high-performance liquid
chromatography (Bio-Rad Variant Hemo-
globin Testing System; Bio-Rad, Her-
cules, CA) with standardized conversion
to A1C values (normal range 4.2–6.3%)
was used. C-peptide was measured by ra-
dioimmunoassay with human C-peptide
kits (Linco Research, St. Charles, MO).
Blood pressure was measured using a Di-
namap monitor or a standard mercury
sphygmomanometer. To account for any
effect of differential measurement error,
blood pressure measurements were ad-
justed as described previously (11). Hy-
pertension was defined as being present if
systolic blood pressure was140 mmHg,
if diastolic blood pressure was 90
mmHg, or if the participant reported cur-
rent treatment for hypertension. Height
and weight were measured in light cloth-
ing by a trained observer. BMI was calcu-
lated as weight in kilograms divided by
the square of height in meters. Informa-
tion on smoking, medications, and his-
tory of diabetes were obtained by
interview.
Statistical methods
Data analysis was performed with SPSS
(version 14.0.0 for Windows; SPSS, Chi-
cago, IL). Descriptive information for
each of the variables was derived, and dis-
tribution was assessed. Logistic regres-
sion modeling was used to assess risk
factors for incident retinopathy among
those with diabetes. Only factors identi-
fied to be significantly associated with in-
cident retinopathy at model 2 were
include in the multivariate model (model
3). Logistic regression was also used to
determine the association of baseline ret-
inopathy with incident diabetes.
RESULTS
Incident retinopathy
The 5-year incidence of retinopathy by
glucose metabolism is shown in Table 1.
The incidences of mild, moderate, and se-
vere nonproliferative diabetic retinopathy
(NPDR) among those with known diabe-
tes were 9.7, 2.8, and 0.7%, respectively.
Proliferative diabetic retinopathy (PDR)
developed in 0.7%. Among those with
newly diagnosed diabetes at baseline, no
incident cases of PDR were identified. Of
those with known diabetes and mild
Table 1—Five-year incidence of retinopathy by baseline glucose tolerance status and age-
group: the AusDiab study
Glucose tolerance status n
Retinopathy incidence in age-group
25
years
25–44
years
45–64
years
65
years
NGT at baseline 227 1.8 1.2 3.0 0
IFG/IGT at baseline 557 0.7 0.0 1.0 0.6
NDM at baseline 168 3.0 0.0 2.0 5.9
KDM at baseline 144 13.9 0.0 15.2 14.0
Data are numbers and percentages (%). IFG, impaired fasting glucose; IGT, impaired glucose tolerance;
NDM, newly diagnosed diabetes; KDM, known diagnosed diabetes.
Glycemia and retinopathy over 5 years
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NPDR at baseline, 50% at follow-up had
no evidence of retinopathy and 17.6%
had progressed, including 2.9% who had
developed PDR. Four of the five partici-
pants with evidence of retinopathy at
baseline and PDR at follow-up had under-
gone laser treatment. Of those with
known diabetes and incident retinopathy,
76% failed to meet the target for glycemic
control of 7% (12) and 88% failed to
meet targets for blood pressure control of
130/85 mmHg (13). Incident macular
edema occurred in 4.8% of participants
with known diabetes, and this was bilat-
eral in four participants. Five of the eight
participants with incident macular edema
had undergone laser treatment.
Among those with diabetes, factors
significantly associated with incident ret-
inopathy in univariate analysis are shown
in Table 2. Logistic regression identified
systolic blood pressure, FPG, and C-
peptide as independent factors associated
with incident retinopathy (after adjust-
ment for age and BMI) (Table 3). Replac-
ing FPG in the model with A1C improved
the strength of the retinopathy association
with hyperglycemia (odds ratio [OR] for
A1C 2.32; P  0.001). However, the as-
sociation with age and BMI were attenu-
ated (data not shown).
Baseline retinopathy and incident
diabetes
Of those who developed incident newly
diagnosed diabetes at follow-up, 11.9%
had retinopathy at baseline compared
with 5.6% of those who did not progress
to incident newly diagnosed diabetes
(P  0.037). Among those with incident
known diabetes identified in between ex-
aminations (n 0), none had retinopathy
signs at baseline. Those with evidence of
retinopathy present at baseline who later
progressed to incident newly diagnosed
diabetes all had NPDR at baseline. After
adjustment for factors identified in uni-
variate analysis (Table 4, model 1) as risk
factors for diabetes (FPG, triglycerides,
and waist circumference), participants
with retinopathy signs at baseline were
twice as likely to develop incident newly
diagnosed diabetes compared with those
who did not have retinopathy signs at
baseline (OR 2.66 [95% CI 1.14–6.21]).
CONCLUSIONS— There were two
principal findings in this population-
based prospective study in Australia.
First, we report on the 5-year incidence of
retinopathy among individuals in differ-
ent categories of glycemia. Our study is
one of a few national studies assessing ret-
inopathy signs across the spectrum of hy-
perglycemia and impaired glucose
metabolism as defined by an oral glucose
tolerance test. We found a relatively low
5-year incidence of retinopathy across
categories of glucose metabolism. Sec-
ond, we report on the longitudinal rela-
Table 2—Characteristics of the population at baseline (diabetes only)
No retinopathy Incident retinopathy P value
n 287 25
Age (years) 60  11 63  10 0.175
Male sex (%) 53 60 0.499
FPG (mmol/l) 7.6  1.9 10.8  3.8 0.001
2-h plasma glucose (mmol/l)* 12.4  3.6 16.2  6.9 0.006
A1C (%) 6.3  1.2 8.5  1.9 0.001
C-peptide (ng/ml) 3.9  1.7 2.9  1.8 0.007
Known diabetes (%) 43 80 0.001
Duration of diabetes (years)† 0 (0–3) 5 (2–9) 0.001
Taking insulin or tablets (%) 57 90 0.007
BMI (kg/m²) 30.4  5.9 29.1  6.1 0.296
Waist circumference (cm) 101.4  13.7 98.8  12.9 0.366
Albumin-to-creatinine ratio
(mg/mmol)
0.8 (0.5–1.6) 1.2 (0.5–4.5) 0.115
Lipid treatment (%) 26 28 0.001
HDL cholesterol (mmol/l) 1.2  0.3 1.2  0.4 0.971
Total cholesterol (mmol/l) 5.7  1.0 5.2  0.9 0.026
Triglycerides (mmol/l) 1.9 (1.3–2.8) 1.7 (0.8–2.6) 0.189
Current smoker (%) 10 4 0.334
Hypertension (%) 40 40 0.313
SBP (mmHg) 142  18 152  23 0.005
DBP (mmHg) 75  12 78  14 0.334
Data are means  SD or median (interquartile range). *Those with KDM and on current treatment with
tablets or insulin did not undergo an oral glucose tolerance test. †Newly diagnosed participants given
duration of zero. DBP, diastolic blood pressure; SBP, systolic blood pressure.
Table 3—ORs (95% CI) of risk factors for incident retinopathy among those with diabetes at
baseline
Incident retinopathy
Model 1: adjusted for age (years) 1.03 (0.98–1.07)
Model 2: one by one adjustment
Model 1 and sex 0.72 (0.31–1.67)
Model 1 and BMI (kg/m²) 0.97 (0.99–1.05)
Model 1 and SBP (mmHg) 1.03 (1.01–1.06)
Model 1 and total cholesterol (mmol/l) 0.80 (0.23–2.80)
Model 1 and FPG (mmol/l) 1.52 (1.30–1.77)
Model 1 and A1C (%) 2.29 (1.75–3.02)
Model 1 and PLG (mmol/l) 1.24 (1.07–1.45)
Model 1 and C-peptide (ng/ml) 0.69 (0.53–0.91)
Model 1 and duration of diabetes (years) 1.06 (1.02–1.12)
Model 1 and smoking 1.61 (0.69–3.75)
Model 3: multivariate adjustment for
C-peptide (ng/ml) 0.56 (0.38–0.83)
FPG (mmol/l) 1.56 (1.32–1.85)
BMI (kg/m²) 1.03 (0.93–1.14)
SBP (mmHg) 1.04 (1.02–1.07)
Age (years) 1.04 (0.99–1.09)
Model 1: OR for retinopathy by age. Model 2: OR for incident retinopathy for each factor (sex, BMI, systolic
blood pressure [SBP], total cholesterol, FPG, A1C, PLG, C-peptide, duration of diabetes, and smoking)
adjusted for age. Model 3: OR of incident retinopathy for C-peptide, FPG, BMI, SBP, and age (adjusted for
each other). PGL, postload glucose.
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tionship of baseline retinopathy with
incidence of diabetes. We showed that
nondiabetic individuals with retinopathy
signs at baseline had a twofold higher risk
of developing incident newly diagnosed
diabetes 5 years later.
Our study should be compared with
the few other prospective studies avail-
able. The 5-year incidence of retinopathy
among those with known diabetes was
similar to the 5-year incidence observed
in the Melbourne Visual Impairment
study (11%) and the 9-year incidence ob-
served in the Hoorn study (17.5%)
(1,14). However, these estimates are con-
siderably lower than those observed in the
majority of previous population-based
studies (15,16). In the Barbados Eye
Study of adults aged 40–84 years, the
4-year incidence of diabetic retinopathy
was 32%; in the Blue Mountains Eye
Study of adults aged 49 years, the
5-year incidence was 22%; and in the San
Luis Valley eye study the 4-year incidence
was 23% (15,16). There are several pos-
sible reasons for this difference in inci-
dence. First, there are differences in
diabetes duration and glycemic control
among studies. The participants in the
AusDiab study had a relatively short du-
ration of diabetes. We showed that reti-
nopathy incidence was highest (34%)
among participants with the longest du-
ration of diabetes (8 years) and worst
glycemic control (A1C 6.7%) com-
pared with just 1% among those with
shorter diabetes duration and lower levels
of A1C. Second, differences in frequency
of other risk factors (e.g., hypertension)
may also partly explain difference in inci-
dence across studies. Finally, differing
methods for ascertaining retinopathy
would have an impact on the reported in-
cidence (16–18).
In the current study, 17.6% of those
with mild NPDR at baseline (known dia-
betes and newly diagnosed diabetes) had
progressed to moderate NPDR (14.7%) or
PDR (2.9%) by follow-up. Of those with
moderate NPDR at baseline, 50% (known
diabetes and newly diagnosed diabetes)
had moderate NPDR at follow-up and
50% had regressed to mild NPDR. Previ-
ous research has shown that those with
moderate NPDR are more likely to
progress to PDR than show signs of re-
gression (19). This finding, along with the
improvement among those with mild
NPDR (in 50% of patients), suggests that
part of this population may be well
treated. Regression of mild NPDR has
been observed previously (14,18,19) and
is possibly related to improved metabolic
control and blood pressure.
The 5-year incidence of retinopathy
among those with NGT and impaired glu-
cose metabolism at baseline was also rel-
atively low in contrast to that in other
studies (1,2,18,20). In the Hoorn study,
which determined the 9-year incidence of
retinopathy among individuals aged
50–74 years, the incidence of retinopathy
was 7% among those with NGT and 14%
among those with impaired glucose me-
tabolism (1). In the Atherosclerosis Risk
in Communities Study, the 3-year inci-
dence of retinopathy among those with-
out diabetes was 2.9%, and the incidence
increased with age from 2% among those
aged 50–54 years to 5.2% among those
aged 65–73 years (18). The Blue Moun-
tains Eye Study reported a 5-year inci-
dence of 9.7% among those aged 49
years (2), and the Beaver Dam Eye Study
reported an incidence of 6% among those
aged 55–74 years (20). The strong associ-
ation between age and retinopathy may
partly explain the difference in incidence
of retinopathy among those without
diabetes across different studies. Other
factors, including the presence of hyper-
tension and differing methods for ascer-
taining retinopathy, would also have an
impact on the reported incidence.
Independent risk factors for retinop-
athy among those with diabetes (both
previously and newly diagnosed diabetes
at baseline) were C-peptide, FPG, and
blood pressure. Both FPG and blood pres-
sure are known for their strong associa-
tion with diabetic retinopathy. The Hoorn
study showed that those with retinopathy
had higher glycemic values and were hy-
pertensive (1); a similar finding was
shown in the Atherosclerosis Risk in
Communities study (18). The UK Pro-
spective Diabetes Study (UKPDS), a clin-
ical trial of 4,585 people with type 2
diabetes, showed that intensive glycemic
and blood pressure control significantly
reduced the incidence and progression of
retinopathy and visual loss (21). The
study additionally showed that intensive
treatment of both risk factors had an ad-
ditive effect (22). In the present study
76% of participants with incident reti-
nopathy failed to meet the target for gly-
cemic control of 7% (12) and 88%
failed to meet targets for blood pressure
control of130/85 mmHg (13). More ag-
gressive management of modifiable risk
factors could reduce the numbers of indi-
viduals who develop retinopathy.
Our second principal finding was the
Table 4—ORs (95% CI) for retinopathy as a risk factor for incident newly diagnosed diabetes
(those with diabetes at baseline excluded)
Incident diabetes
Model 1: One by one adjustment:
Baseline retinopathy 2.37 (1.06–5.28)
FPG (mmol/l) 3.05 (1.91–4.87)
SBP (mmHg) 1.01 (0.99–1.02)
Total cholesterol (mmol/l) 1.16 (0.90–1.49)
Triglycerides (mmol/l) 2.21 (1.43–3.41)
Waist circumference (cm) 1.04 (1.02–1.06)
Age (years) 1.01 (0.99–1.03)
Sex 0.75 (0.45–1.24)
Current smoking 1.41 (0.65–3.09)
Model 2: adjusted for age and sex
Baseline retinopathy 2.31 (1.03–5.16)
FPG (mmol/l) 3.05 (1.86–4.98)
Triglycerides (mmol/l) 2.14 (1.38–3.32)
Waist circumference (cm) 1.04 (1.01–1.06)
Model 3: multivariate adjustment for
Baseline retinopathy 2.66 (1.14–6.21)
FPG (mmol/l) 2.56 (1.54–4.24)
Triglycerides (mmol/l) 1.82 (1.13–2.93)
Waist circumference (cm) 1.01 (0.99–1.04)
Model 1: univariate association of baseline retinopathy, FPG, triglycerides, waist circumference, age, sex, and
smoking with incident diabetes. Model 2: association of retinopathy, FPG, triglycerides and waist circum-
ference with incident diabetes (adjusted for age and sex). Model 3: association of baseline retinopathy, FPG,
triglycerides, and waist circumference with incident diabetes (adjusted for each other). SBP, systolic blood
pressure.
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demonstration of a twofold risk of devel-
opment of incident newly diagnosed dia-
betes among nondiabetic individuals with
retinopathy signs at baseline. We should
emphasize that the majority of those with
retinopathy at baseline did not go on to
develop incident newly diagnosed diabe-
tes (only 8 of 67 participants progressed).
No cases of retinopathy were identified
among those with incident known diabe-
tes. However, the association of retinopa-
thy with incident newly diagnosed
diabetes was significant and similar to the
strength of the association of FPG with
incident diabetes (Table 4). This associa-
tion is consistent with results from the
Beaver Dam Eye Study (23), the Athero-
sclerosis in Communities study (7), and
the Blue Mountains Eye Study (24). The
Beaver Dam Eye Study showed that reti-
nopathy among those without diabetes at
baseline was associated with the 15-year
incidence of diabetes (among those aged
65 years) (23). The Blue Mountains Eye
Study, which reexamined 2,335 adults
aged 49 years, showed that among
those with retinopathy and free of diabe-
tes at baseline, the incidence of diabetes
was 3.5% (24). The authors highlighted
the fact that for the majority of partici-
pants, in those without diabetes, there
was no association of vascular retinopathy
signs with blood glucose and suggested
that the association was likely to have
many etiologies, with older age and blood
pressure being the major contributing
factors. Further research is needed in this
area to clarify the importance of retinopa-
thy in relation to the incidence of diabetes.
The present study has several limita-
tions. Duration of diabetes was based on
self-report, without confirmation from
medical records. Age, A1C, and slight dif-
ference in the prevalence of retinopathy
between responders and nonresponders
probably caused a slight underestimation
of the incidence. A relatively small num-
ber of individuals with retinopathy were
identified in this study. Therefore, only
factors very strongly associated with inci-
dent retinopathy and diabetes were de-
tectable. A longer follow-up time may see
additional associations identified, includ-
ing microalbuminuria, which at this point
was not shown to be associated with inci-
dent retinopathy. No measures of genetic
factors were assessed in this study. Ge-
netic differences between populations may
be a strong governing factor in the develop-
ment and progression of retinopathy.
In summary, we report the 5-year in-
cidence of retinopathy in a national pop-
ulation-based cohort study. The present
study showed that the incidence of reti-
nopathy in Australia is relatively low com-
pared with that seen in older studies. We
identified a twofold risk of development
of incident newly diagnosed diabetes
among participants without diabetes
who had retinopathy at baseline. This
result suggests that mild background
retinopathy may be a preclinical marker
of microvascular disease and future dia-
betes risk and may identify a particular
high-risk group for possible early inter-
vention. This suggestion clearly warrants
further investigation.
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